ReviewBioengineering (Basel, Switzerland)2018
Towards Multi-Organoid Systems for Drug Screening Applications.
Review in Bioengineering (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Understanding the use of spheroids and pellets in the chondrogenic differentiation of human stem cells.Osteoarthritis and cartilage open · 2026Article
- Cartilage repair: unleashing PRP's potential in organoid models.Cytotechnology · 2025Review
- Engineering the 3D structure of organoids.Stem cell reports · 2025Review
- (3D) Bioprinting-Next Dimension of the Pharmaceutical Sector.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") forFrontiers in medicine · 2024Review
- Spheroids and organoids derived from colorectal cancer as tools forExploration of targeted anti-tumor therapy · 2024Review
- Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.Cardiovascular research · 2023Review
- Analysis of the effects of bench-scale cell culture platforms and inoculum cell concentrations on PSC aggregate formation and culture.Frontiers in bioengineering and biotechnology · 2023Article
- Key aspects for conception and construction of co-culture models of tumor-stroma interactions.Frontiers in bioengineering and biotechnology · 2023Review
- Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review.ADMET & DMPK · 2023Review
- Review
- Everything You Always Wanted to Know About Organoid-Based Models (and Never Dared to Ask).Cellular and molecular gastroenterology and hepatology · 2022Review
- From Spheroids to Organoids: The Next Generation of Model Systems of Human Cardiac Regeneration in a Dish.International journal of molecular sciences · 2021Review
- Recent advances in microarray 3D bioprinting for high-throughput spheroid and tissue culture and analysis.Essays in biochemistry · 2021Review
- Ethical Challenges in Organoid Use.Biotech (Basel (Switzerland)) · 2021Article
- Patient-Specific Organoid and Organ-on-a-Chip: 3D Cell-Culture Meets 3D Printing and Numerical Simulation.Advanced biology · 2021Review
- Article
- Cardiac organoid - a promising perspective of preclinical model.Stem cell research & therapy · 2021Review
- Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistance.Genes & diseases · 2021Article
- Organ-on-a-Chip systems for new drugs development.ADMET & DMPK · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A low percentage of novel drug candidates succeed and reach the end of the drug discovery pipeline, mainly due to poor initial screening and assessment of the effects of the drug and its metabolites over various tissues in the human body. For that, emerging technologies involving the production of organoids from human pluripotent stem cells (hPSCs) and the use of organ-on-a-chip devices are showing great promise for developing a more reliable, rapid and cost-effective drug discovery process when compared with the current use of animal models. In particular, the possibility of virtually obtaining any type of cell within the human body, in combination with the ability to create patient-specific tissues using human induced pluripotent stem cells (hiPSCs), broadens the horizons in the fields of drug discovery and personalized medicine. In this review, we address the current progress and challenges related to the process of obtaining organoids from different cell lineages emerging from hPSCs, as well as how to create devices that will allow a precise examination of the in vitro effects generated by potential drugs in different organ systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.